CompanyOverview\|NYSE:PFE] A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income- ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) is planning to host its first meeting under new agency commissioner Marty Makary, M.D. As head of the FDA’s oncology department, Richard ...

However, Pfizer could hold off on the acquisitions front to see how its obesity drug PF-07976016 fares in clinical testing. The market for obesity drugs presents one of the most lucrative targets ...

Could Pfizer solve the issue by acquiring an up-and-coming biotech with a promising obesity drug in clinical development? The good news for Pfizer is that it shouldn't have any problems finding an ...

Among Pfizer's precision oncology products, revenues for Ibrance (palbociclib), a CDK4/6 inhibitor used to treat hormone receptor (HR)-positive and HER2-negative breast cancer that is Pfizer's ...

formerly the top regulator of the drug division of the Food and Drug Administration, will join Pfizer as chief medical officer, a role in which she will lead the drug firm’s regulatory ...

The former head of the Food and Drug Administration’s (FDA) drug division is joining Pfizer as its chief medical officer, the company announced Monday. Patrizia Cavazzoni was formerly director of the ...

Pfizer (NYSE:PFE) reported positive results from a Phase 3 study of its drug Talzenna in combination with Xtandi in the treatment of certain patients with prostate cancer. The study, called ...

The results have been shared with global health authorities, including the FDA and the European Medicines Agency (EMA), to support potential updates to the approved labels for TALZENNA.

(RTTNews) - Pfizer Inc. (PFE ... with mCRPC compared to Xtandi alone. Talzenna in combination with Xtandi is already approved by the U.S. Food and Drug Administration (FDA) for the treatment ...